Background
Phase 3, open-label, randomized controlled trial (ECOG-ACRIN E1912). N=529 previously untreated CLL/SLL patients aged ≤70 years without del(17p)/TP53 mutation. Randomized 2:1 (IR vs FCR). Key trial comparing ibrutinib+rituximab to the FCR standard of care in younger, fit CLL patients. Median age 58 years; predominantly ECOG PS 0–1.
Interventions and follow up
Arm A: Ibrutinib 420 mg PO daily continuously + rituximab 375 mg/m² IV weekly × 4 doses (cycle 1) then monthly × 5 doses (cycles 2–6) (N=354)
Arm B: FCR: fludarabine 25 mg/m² IV days 1–3 + cyclophosphamide 250 mg/m² days 1–3 + rituximab 375/500 mg/m², 6 cycles q28d (N=175)
Primary endpoint: Progression-free survival (PFS)
Median follow up: 33.4 months (primary); 5+ years (JCO 2022 update)
Arm B: FCR: fludarabine 25 mg/m² IV days 1–3 + cyclophosphamide 250 mg/m² days 1–3 + rituximab 375/500 mg/m², 6 cycles q28d (N=175)
Primary endpoint: Progression-free survival (PFS)
Median follow up: 33.4 months (primary); 5+ years (JCO 2022 update)
Results
3-yr PFS: 89.4% vs 72.9% (IR vs FCR), HR 0.35 (95% CI 0.22–0.56), P<.001
3-yr OS: 98.8% vs 91.5%, HR 0.17 (95% CI 0.05–0.54), P=.001
IGHV-unmutated PFS (HR): 0.26 (95% CI 0.14–0.50) — greatest benefit
IGHV-mutated PFS (HR): 0.44 (95% CI 0.21–0.92) — benefit maintained
3-yr OS: 98.8% vs 91.5%, HR 0.17 (95% CI 0.05–0.54), P=.001
IGHV-unmutated PFS (HR): 0.26 (95% CI 0.14–0.50) — greatest benefit
IGHV-mutated PFS (HR): 0.44 (95% CI 0.21–0.92) — benefit maintained
Adverse events
Hematologic: Grade ≥3 hematologic AEs 41% (IR) vs 72% (FCR).
Infections: Grade ≥3 infections 17% (IR) vs 28% (FCR) — significantly lower with IR; grade ≥3 febrile neutropenia 1% (IR) vs 9% (FCR).
Cardiovascular: Grade ≥3 atrial fibrillation 7.5% (IR) vs 1.7% (FCR).
Tolerability: Discontinuation due to AEs 14% (IR) vs 26% (FCR) at 3 years.
Infections: Grade ≥3 infections 17% (IR) vs 28% (FCR) — significantly lower with IR; grade ≥3 febrile neutropenia 1% (IR) vs 9% (FCR).
Cardiovascular: Grade ≥3 atrial fibrillation 7.5% (IR) vs 1.7% (FCR).
Tolerability: Discontinuation due to AEs 14% (IR) vs 26% (FCR) at 3 years.
Conclusions
Ibrutinib+rituximab demonstrated significantly superior PFS and, notably, a meaningful OS benefit compared with FCR in young, fit treatment-naive CLL patients without TP53 abnormalities. E1912 was the first randomized trial to show an OS benefit for a BTKi-based regimen over chemoimmunotherapy in CLL, shifting the treatment paradigm for fit younger patients.
Key Limitations
Del(17p)/TP53 patients were excluded — a population in which targeted therapy is unambiguously superior. The ibrutinib+rituximab combination has not been shown superior to ibrutinib monotherapy (Alliance A041202); the rituximab component may be superfluous. Long-term ibrutinib accumulates toxicities (AFib, hypertension), and 26% discontinue within 3 years. For IGHV-mutated CLL, FCR may provide long-term remissions approaching functional cure; whether IR achieves higher cure rates is unknown without longer follow-up. CLL17 subsequently demonstrated non-inferiority of fixed-duration venetoclax-based regimens to continuous ibrutinib.
Clinical Context
E1912 established BTKi superiority over FCR in fit CLL and demonstrated an OS advantage — a landmark finding. However, ibrutinib monotherapy (not IR) is the current BTKi standard; next-generation BTKi (acalabrutinib, zanubrutinib) have better cardiac safety. FLAIR showed MRD-guided ibrutinib+venetoclax superior to both IR and FCR with potential for treatment cessation. For younger patients with IGHV-mutated CLL, FCR remains a curative option at many centers. ESMO-MCBS: 5.